#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-9	Increased	_
1-2	10-14	BOLD	_
1-3	15-22	Signals	_
1-4	23-31	Elicited	_
1-5	32-34	by	_
1-6	35-39	High	_
1-7	40-45	Gamma	_
1-8	46-54	Auditory	_
1-9	55-66	Stimulation	_
1-10	67-69	of	_
1-11	70-73	the	_
1-12	74-78	Left	_
1-13	79-87	Auditory	_
1-14	88-94	Cortex	_
1-15	95-97	in	_
1-16	98-103	Acute	http://maven.renci.org/NeuroBridge/neurobridge#ChronicSchizophrenia
1-17	104-109	State	http://maven.renci.org/NeuroBridge/neurobridge#ChronicSchizophrenia
1-18	110-123	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#ChronicSchizophrenia
1-19	124-130	Recent	_
1-20	131-134	MRI	_
1-21	135-142	studies	_
1-22	143-147	have	_
1-23	148-153	shown	_
1-24	154-158	that	_
1-25	159-172	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-26	173-175	is	_
1-27	176-189	characterized	_
1-28	190-192	by	_
1-29	193-203	reductions	_
1-30	204-206	in	_
1-31	207-212	brain	_
1-32	213-217	gray	_
1-33	218-224	matter	_
1-34	225-226	,	_
1-35	227-232	which	_
1-36	233-241	progress	_
1-37	242-244	in	_
1-38	245-248	the	_
1-39	249-254	acute	_
1-40	255-260	state	_
1-41	261-263	of	_
1-42	264-267	the	_
1-43	268-275	disease	_
1-44	276-277	.	_

2-1	278-286	Cortical	_
2-2	287-296	circuitry	_
2-3	297-310	abnormalities	_
2-4	311-313	in	_
2-5	314-319	gamma	_
2-6	320-332	oscillations	_
2-7	333-334	,	_
2-8	335-339	such	_
2-9	340-342	as	_
2-10	343-351	deficits	_
2-11	352-354	in	_
2-12	355-358	the	_
2-13	359-367	auditory	_
2-14	368-374	steady	_
2-15	375-380	state	_
2-16	381-389	response	_
2-17	390-391	(	_
2-18	392-396	ASSR	_
2-19	397-398	)	_
2-20	399-401	to	_
2-21	402-407	gamma	_
2-22	408-417	frequency	_
2-23	418-419	(	_
2-24	420-421	>	_
2-25	422-427	30-Hz	_
2-26	428-429	)	_
2-27	430-441	stimulation	_
2-28	442-443	,	_
2-29	444-448	have	_
2-30	449-453	also	_
2-31	454-458	been	_
2-32	459-467	reported	_
2-33	468-470	in	_
2-34	471-484	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-35	485-493	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-36	494-495	.	_

3-1	496-498	In	_
3-2	499-502	the	_
3-3	503-510	current	_
3-4	511-516	study	_
3-5	517-518	,	_
3-6	519-521	we	_
3-7	522-534	investigated	_
3-8	535-541	neural	_
3-9	542-551	responses	_
3-10	552-558	during	_
3-11	559-564	click	_
3-12	565-576	stimulation	_
3-13	577-579	by	_
3-14	580-584	BOLD	_
3-15	585-592	signals	_
3-16	593-594	.	_

4-1	595-597	We	_
4-2	598-606	acquired	_
4-3	607-611	BOLD	_
4-4	612-621	responses	_
4-5	622-630	elicited	_
4-6	631-633	by	_
4-7	634-639	click	_
4-8	640-646	trains	_
4-9	647-649	of	_
4-10	650-652	20	_
4-11	653-654	,	_
4-12	655-657	30	_
4-13	658-659	,	_
4-14	660-662	40	_
4-15	663-666	and	_
4-16	667-672	80-Hz	_
4-17	673-684	frequencies	_
4-18	685-689	from	_
4-19	690-692	15	_
4-20	693-701	patients	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
4-21	702-706	with	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
4-22	707-712	acute	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
4-23	713-720	episode	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
4-24	721-734	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
4-25	735-736	(	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
4-26	737-741	AESZ	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
4-27	742-743	)	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
4-28	744-745	,	_
4-29	746-748	14	_
4-30	749-773	symptom-severity-matched	http://maven.renci.org/NeuroBridge/neurobridge#InsomniaSeverityIndex
4-31	774-782	patients	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
4-32	783-787	with	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
4-33	788-797	non-acute	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
4-34	798-805	episode	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
4-35	806-819	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
4-36	820-821	(	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
4-37	822-826	NASZ	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
4-38	827-828	)	http://maven.renci.org/NeuroBridge/neurobridge#AcuteSchizophrenicEpisode
4-39	829-830	,	_
4-40	831-834	and	_
4-41	835-837	24	_
4-42	838-845	healthy	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
4-43	846-854	controls	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
4-44	855-856	(	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
4-45	857-859	HC	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
4-46	860-861	)	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
4-47	862-863	,	_
4-48	864-872	assessed	_
4-49	873-876	via	_
4-50	877-878	a	_
4-51	879-887	standard	_
4-52	888-895	general	_
4-53	896-914	linear-model-based	_
4-54	915-923	analysis	_
4-55	924-925	.	_

5-1	926-929	The	_
5-2	930-934	AESZ	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
5-3	935-940	group	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
5-4	941-947	showed	_
5-5	948-961	significantly	_
5-6	962-971	increased	_
5-7	972-981	ASSR-BOLD	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
5-8	982-989	signals	_
5-9	990-992	to	_
5-10	993-998	80-Hz	_
5-11	999-1006	stimuli	_
5-12	1007-1009	in	_
5-13	1010-1013	the	_
5-14	1014-1018	left	_
5-15	1019-1027	auditory	_
5-16	1028-1034	cortex	_
5-17	1035-1043	compared	_
5-18	1044-1048	with	_
5-19	1049-1052	the	_
5-20	1053-1055	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-21	1056-1059	and	_
5-22	1060-1064	NASZ	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
5-23	1065-1071	groups	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
5-24	1072-1073	.	_

6-1	1074-1076	In	_
6-2	1077-1085	addition	_
6-3	1086-1087	,	_
6-4	1088-1096	enhanced	_
6-5	1097-1102	80-Hz	_
6-6	1103-1112	ASSR-BOLD	_
6-7	1113-1120	signals	_
6-8	1121-1125	were	_
6-9	1126-1136	associated	_
6-10	1137-1141	with	_
6-11	1142-1146	more	_
6-12	1147-1153	severe	_
6-13	1154-1162	auditory	_
6-14	1163-1176	hallucination	_
6-15	1177-1188	experiences	_
6-16	1189-1191	in	_
6-17	1192-1196	AESZ	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence
6-18	1197-1209	participants	http://maven.renci.org/NeuroBridge/neurobridge#MethamphetamineDependence
6-19	1210-1211	.	_

7-1	1212-1215	The	_
7-2	1216-1223	present	_
7-3	1224-1231	results	_
7-4	1232-1240	indicate	_
7-5	1241-1245	that	_
7-6	1246-1252	neural	_
7-7	1253-1257	over	_
7-8	1258-1268	activation	_
7-9	1269-1275	occurs	_
7-10	1276-1282	during	_
7-11	1283-1288	80-Hz	_
7-12	1289-1297	auditory	_
7-13	1298-1309	stimulation	_
7-14	1310-1312	of	_
7-15	1313-1316	the	_
7-16	1317-1321	left	_
7-17	1322-1330	auditory	_
7-18	1331-1337	cortex	_
7-19	1338-1340	in	_
7-20	1341-1352	individuals	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
7-21	1353-1357	with	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
7-22	1358-1363	acute	http://maven.renci.org/NeuroBridge/neurobridge#ChronicSchizophrenia
7-23	1364-1369	state	http://maven.renci.org/NeuroBridge/neurobridge#ChronicSchizophrenia
7-24	1370-1383	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#ChronicSchizophrenia
7-25	1384-1385	.	_

8-1	1386-1391	Given	_
8-2	1392-1395	the	_
8-3	1396-1404	possible	_
8-4	1405-1416	association	_
8-5	1417-1424	between	_
8-6	1425-1433	abnormal	_
8-7	1434-1439	gamma	_
8-8	1440-1448	activity	_
8-9	1449-1452	and	_
8-10	1453-1462	increased	_
8-11	1463-1472	glutamate	_
8-12	1473-1479	levels	_
8-13	1480-1481	,	_
8-14	1482-1485	our	_
8-15	1486-1490	data	_
8-16	1491-1494	may	_
8-17	1495-1502	reflect	_
8-18	1503-1512	glutamate	_
8-19	1513-1521	toxicity	_
8-20	1522-1524	in	_
8-21	1525-1528	the	_
8-22	1529-1537	auditory	_
8-23	1538-1544	cortex	_
8-24	1545-1547	in	_
8-25	1548-1551	the	_
8-26	1552-1557	acute	_
8-27	1558-1563	state	_
8-28	1564-1566	of	_
8-29	1567-1580	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
8-30	1581-1582	,	_
8-31	1583-1588	which	_
8-32	1589-1594	might	_
8-33	1595-1599	lead	_
8-34	1600-1602	to	_
8-35	1603-1614	progressive	_
8-36	1615-1622	changes	_
8-37	1623-1625	in	_
8-38	1626-1629	the	_
8-39	1630-1634	left	_
8-40	1635-1645	transverse	_
8-41	1646-1654	temporal	_
8-42	1655-1660	gyrus	_
8-43	1661-1662	.	_

9-1	1663-1673	Highlights	_
9-2	1674-1676	We	_
9-3	1677-1689	investigated	_
9-4	1690-1696	neural	_
9-5	1697-1706	responses	_
9-6	1707-1713	during	_
9-7	1714-1719	click	_
9-8	1720-1731	stimulation	_
9-9	1732-1734	by	_
9-10	1735-1739	BOLD	_
9-11	1740-1747	signals	_
9-12	1748-1749	.	_

10-1	1750-1752	We	_
10-2	1753-1762	evaluated	_
10-3	1763-1771	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-4	1772-1776	with	_
10-5	1777-1782	acute	http://maven.renci.org/NeuroBridge/neurobridge#AcutePain
10-6	1783-1786	and	_
10-7	1787-1796	non-acute	_
10-8	1797-1810	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-9	1811-1812	,	_
10-10	1813-1816	and	_
10-11	1817-1824	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
10-12	1825-1833	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
10-13	1834-1835	.	_

11-1	1836-1841	80-Hz	_
11-2	1842-1850	auditory	_
11-3	1851-1862	stimulation	_
11-4	1863-1872	activated	_
11-5	1873-1876	the	_
11-6	1877-1881	left	_
11-7	1882-1890	auditory	_
11-8	1891-1897	cortex	_
11-9	1898-1900	in	_
11-10	1901-1906	acute	_
11-11	1907-1920	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-12	1921-1922	.	_

12-1	1923-1926	Our	_
12-2	1927-1931	data	_
12-3	1932-1935	may	_
12-4	1936-1943	reflect	_
12-5	1944-1948	left	_
12-6	1949-1957	auditory	_
12-7	1958-1964	cortex	_
12-8	1965-1974	glutamate	_
12-9	1975-1983	toxicity	_
12-10	1984-1986	in	_
12-11	1987-1992	acute	_
12-12	1993-2006	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-13	2007-2008	.	_

13-1	2009-2015	Recent	_
13-2	2016-2019	MRI	_
13-3	2020-2027	studies	_
13-4	2028-2032	show	_
13-5	2033-2037	that	_
13-6	2038-2051	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
13-7	2052-2054	is	_
13-8	2055-2068	characterized	_
13-9	2069-2071	by	_
13-10	2072-2079	reduced	_
13-11	2080-2085	brain	_
13-12	2086-2090	gray	_
13-13	2091-2097	matter	_
13-14	2098-2099	,	_
13-15	2100-2105	which	_
13-16	2106-2118	deteriorates	_
13-17	2119-2121	in	_
13-18	2122-2125	the	_
13-19	2126-2131	acute	_
13-20	2132-2137	state	_
13-21	2138-2140	of	_
13-22	2141-2144	the	_
13-23	2145-2152	disease	_
13-24	2153-2154	.	_

14-1	2155-2163	Periodic	_
14-2	2164-2172	auditory	_
14-3	2173-2178	click	_
14-4	2179-2185	trains	_
14-5	2186-2192	elicit	_
14-6	2193-2201	auditory	_
14-7	2202-2214	steady-state	_
14-8	2215-2224	responses	_
14-9	2225-2226	(	_
14-10	2227-2232	ASSRs	_
14-11	2233-2234	)	_
14-12	2235-2236	,	_
14-13	2237-2240	and	_
14-14	2241-2245	ASSR	http://maven.renci.org/NeuroBridge/neurobridge#BodyMass
14-15	2246-2259	abnormalities	_
14-16	2260-2263	are	_
14-17	2264-2272	reported	_
14-18	2273-2275	in	_
14-19	2276-2289	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
14-20	2290-2291	.	_

15-1	2292-2294	We	_
15-2	2295-2307	investigated	_
15-3	2308-2314	neural	_
15-4	2315-2324	responses	_
15-5	2325-2331	during	_
15-6	2332-2337	click	_
15-7	2338-2349	stimulation	_
15-8	2350-2355	using	_
15-9	2356-2360	BOLD	_
15-10	2361-2368	signals	_
15-11	2369-2370	,	_
15-12	2371-2376	which	_
15-13	2377-2380	may	_
15-14	2381-2388	reflect	_
15-15	2389-2398	glutamate	_
15-16	2399-2407	toxicity	_
15-17	2408-2409	.	_

16-1	2410-2418	Compared	_
16-2	2419-2423	with	_
16-3	2424-2433	non-acute	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
16-4	2434-2447	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
16-5	2448-2456	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
16-6	2457-2460	and	_
16-7	2461-2468	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
16-8	2469-2477	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
16-9	2478-2479	,	_
16-10	2480-2485	acute	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
16-11	2486-2493	episode	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
16-12	2494-2507	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
16-13	2508-2516	patients	http://maven.renci.org/NeuroBridge/neurobridge#FirstEpisodePsychosis
16-14	2517-2523	showed	_
16-15	2524-2537	significantly	_
16-16	2538-2547	increased	_
16-17	2548-2557	ASSR-BOLD	_
16-18	2558-2560	to	_
16-19	2561-2566	80-Hz	_
16-20	2567-2574	stimuli	_
16-21	2575-2577	in	_
16-22	2578-2581	the	_
16-23	2582-2586	left	_
16-24	2587-2595	auditory	_
16-25	2596-2602	cortex	_
16-26	2603-2604	.	_

17-1	2605-2608	Our	_
17-2	2609-2613	data	_
17-3	2614-2625	demonstrate	_
17-4	2626-2634	neuronal	_
17-5	2635-2639	over	_
17-6	2640-2650	activation	_
17-7	2651-2653	in	_
17-8	2654-2659	terms	_
17-9	2660-2662	of	_
17-10	2663-2666	the	_
17-11	2667-2671	BOLD	_
17-12	2672-2679	pattern	_
17-13	2680-2682	in	_
17-14	2683-2688	acute	http://maven.renci.org/NeuroBridge/neurobridge#ChronicSchizophrenia
17-15	2689-2694	state	http://maven.renci.org/NeuroBridge/neurobridge#ChronicSchizophrenia
17-16	2695-2708	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#ChronicSchizophrenia
17-17	2709-2710	,	_
17-18	2711-2716	which	_
17-19	2717-2722	might	_
17-20	2723-2730	reflect	_
17-21	2731-2742	progressive	_
17-22	2743-2749	volume	_
17-23	2750-2759	reduction	_
17-24	2760-2762	in	_
17-25	2763-2766	the	_
17-26	2767-2771	left	_
17-27	2772-2780	superior	_
17-28	2781-2789	temporal	_
17-29	2790-2796	cortex	_
17-30	2797-2799	by	_
17-31	2800-2809	glutamate	_
17-32	2810-2818	toxicity	_
17-33	2819-2825	during	_
17-34	2826-2829	the	_
17-35	2830-2835	acute	_
17-36	2836-2841	phase	_
17-37	2842-2844	of	_
17-38	2845-2858	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
17-39	2859-2860	.	_

18-1	2861-2870	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
18-2	2871-2872	&	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
18-3	2873-2880	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
18-4	2881-2893	Participants	_
18-5	2894-2905	Demographic	_
18-6	2906-2909	and	_
18-7	2910-2918	clinical	_
18-8	2919-2923	data	_
18-9	2924-2927	are	_
18-10	2928-2933	shown	_
18-11	2934-2936	in	_
18-12	2937-2942	Table	_
18-13	2943-2944	1	_
18-14	2945-2946	.	_

19-1	2947-2950	The	_
19-2	2951-2957	sample	_
19-3	2958-2967	consisted	_
19-4	2968-2970	of	_
19-5	2971-2973	24	_
19-6	2974-2976	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
19-7	2977-2978	,	_
19-8	2979-2981	15	_
19-9	2982-2986	AESZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
19-10	2987-2988	,	_
19-11	2989-2992	and	_
19-12	2993-2995	14	_
19-13	2996-3020	symptom-severity-matched	http://maven.renci.org/NeuroBridge/neurobridge#InsomniaSeverityIndex
19-14	3021-3025	NASZ	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
19-15	3026-3034	subjects	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
19-16	3035-3036	.	_

20-1	3037-3040	All	_
20-2	3041-3049	subjects	_
20-3	3050-3053	had	_
20-4	3054-3060	normal	_
20-5	3061-3068	hearing	_
20-6	3069-3070	,	_
20-7	3071-3075	were	_
20-8	3076-3083	between	_
20-9	3084-3086	25	_
20-10	3087-3090	and	_
20-11	3091-3093	59	_
20-12	3094-3099	years	_
20-13	3100-3102	of	_
20-14	3103-3106	age	_
20-15	3107-3108	,	_
20-16	3109-3112	and	_
20-17	3113-3117	were	_
20-18	3118-3130	right-handed	_
20-19	3131-3132	.	_

21-1	3133-3138	After	_
21-2	3139-3148	receiving	_
21-3	3149-3150	a	_
21-4	3151-3159	complete	_
21-5	3160-3171	description	_
21-6	3172-3174	of	_
21-7	3175-3178	the	_
21-8	3179-3184	study	_
21-9	3185-3186	,	_
21-10	3187-3190	all	_
21-11	3191-3203	participants	_
21-12	3204-3210	signed	_
21-13	3211-3213	an	_
21-14	3214-3222	informed	_
21-15	3223-3230	consent	_
21-16	3231-3235	form	_
21-17	3236-3245	according	_
21-18	3246-3248	to	_
21-19	3249-3252	the	_
21-20	3253-3264	regulations	_
21-21	3265-3267	of	_
21-22	3268-3271	the	_
21-23	3272-3278	Ethics	_
21-24	3279-3288	Committee	_
21-25	3289-3291	of	_
21-26	3292-3295	the	_
21-27	3296-3304	National	_
21-28	3305-3313	Hospital	_
21-29	3314-3326	Organization	_
21-30	3327-3332	Hizen	_
21-31	3333-3344	Psychiatric	_
21-32	3345-3351	Center	_
21-33	3352-3353	.	_

22-1	3354-3361	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
22-2	3362-3370	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
22-3	3371-3375	were	_
22-4	3376-3384	screened	_
22-5	3385-3390	using	_
22-6	3391-3394	the	_
22-7	3395-3405	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
22-8	3406-3414	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
22-9	3415-3424	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
22-10	3425-3426	(	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
22-11	3427-3431	SCID	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
22-12	3432-3433	)	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
22-13	3434-3446	-non-patient	_
22-14	3447-3454	edition	_
22-15	3455-3456	.	_

23-1	3457-3459	No	_
23-2	3460-3467	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
23-3	3468-3476	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
23-4	3477-3479	or	_
23-5	3480-3485	their	_
23-6	3486-3498	first-degree	_
23-7	3499-3508	relatives	_
23-8	3509-3512	had	_
23-9	3513-3515	an	_
23-10	3516-3522	Axis-I	_
23-11	3523-3534	psychiatric	_
23-12	3535-3543	disorder	_
23-13	3544-3545	.	_

24-1	3546-3549	The	_
24-2	3550-3559	exclusion	_
24-3	3560-3568	criteria	_
24-4	3569-3573	were	_
24-5	3574-3575	:	_
24-6	3576-3577	1	_
24-7	3578-3579	)	_
24-8	3580-3592	neurological	_
24-9	3593-3600	illness	_
24-10	3601-3603	or	_
24-11	3604-3609	major	_
24-12	3610-3614	head	_
24-13	3615-3621	trauma	_
24-14	3622-3623	,	_
24-15	3624-3625	2	_
24-16	3626-3627	)	_
24-17	3628-3636	previous	_
24-18	3637-3646	treatment	_
24-19	3647-3651	with	_
24-20	3652-3669	electroconvulsive	_
24-21	3670-3677	therapy	_
24-22	3678-3679	,	_
24-23	3680-3681	3	_
24-24	3682-3683	)	_
24-25	3684-3691	alcohol	_
24-26	3692-3694	or	_
24-27	3695-3699	drug	_
24-28	3700-3710	dependence	_
24-29	3711-3712	,	_
24-30	3713-3714	4	_
24-31	3715-3716	)	_
24-32	3717-3724	alcohol	_
24-33	3725-3727	or	_
24-34	3728-3732	drug	_
24-35	3733-3738	abuse	_
24-36	3739-3745	within	_
24-37	3746-3749	the	_
24-38	3750-3754	past	_
24-39	3755-3756	5	_
24-40	3757-3762	years	_
24-41	3763-3764	,	_
24-42	3765-3768	and	_
24-43	3769-3770	5	_
24-44	3771-3772	)	_
24-45	3773-3774	a	_
24-46	3775-3781	verbal	_
24-47	3782-3794	intelligence	_
24-48	3795-3803	quotient	_
24-49	3804-3809	below	_
24-50	3810-3812	75	_
24-51	3813-3814	.	_

25-1	3815-3818	All	_
25-2	3819-3827	patients	_
25-3	3828-3832	were	_
25-4	3833-3842	recruited	_
25-5	3843-3847	from	_
25-6	3848-3856	National	_
25-7	3857-3865	Hospital	_
25-8	3866-3878	Organization	_
25-9	3879-3884	Hizen	_
25-10	3885-3896	Psychiatric	_
25-11	3897-3903	Center	_
25-12	3904-3907	and	_
25-13	3908-3912	were	_
25-14	3913-3922	diagnosed	_
25-15	3923-3928	based	_
25-16	3929-3931	on	_
25-17	3932-3935	the	_
25-18	3936-3944	SCID-DSM	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
25-19	3945-3950	IV-TR	_
25-20	3951-3952	,	_
25-21	3953-3961	Research	_
25-22	3962-3969	Version	_
25-23	3970-3973	and	_
25-24	3974-3985	information	_
25-25	3986-3990	from	_
25-26	3991-3998	patient	_
25-27	3999-4006	medical	_
25-28	4007-4014	records	_
25-29	4015-4016	.	_

26-1	4017-4022	Based	_
26-2	4023-4025	on	_
26-3	4026-4034	previous	_
26-4	4035-4042	studies	_
26-5	4043-4044	,	_
26-6	4045-4047	we	_
26-7	4048-4061	operationally	_
26-8	4062-4069	defined	_
26-9	4070-4072	an	_
26-10	4073-4078	acute	_
26-11	4079-4091	exacerbation	_
26-12	4092-4099	episode	_
26-13	4100-4102	as	_
26-14	4103-4107	that	_
26-15	4108-4117	occurring	_
26-16	4118-4124	within	_
26-17	4125-4126	4	_
26-18	4127-4132	weeks	_
26-19	4133-4135	of	_
26-20	4136-4147	psychiatric	_
26-21	4148-4163	hospitalization	_
26-22	4164-4165	,	_
26-23	4166-4169	and	_
26-24	4170-4171	a	_
26-25	4172-4181	non-acute	_
26-26	4182-4187	phase	_
26-27	4188-4190	as	_
26-28	4191-4195	that	_
26-29	4196-4205	occurring	_
26-30	4206-4208	at	_
26-31	4209-4214	least	_
26-32	4215-4216	4	_
26-33	4217-4222	weeks	_
26-34	4223-4228	after	_
26-35	4229-4240	psychiatric	_
26-36	4241-4256	hospitalization	_
26-37	4257-4258	.	_

27-1	4259-4262	All	_
27-2	4263-4267	AESZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
27-3	4268-4271	and	_
27-4	4272-4274	11	_
27-5	4275-4279	NASZ	http://maven.renci.org/NeuroBridge/neurobridge#PlasminAssay
27-6	4280-4292	participants	_
27-7	4293-4297	were	_
27-8	4298-4308	inpatients	_
27-9	4309-4310	,	_
27-10	4311-4314	and	_
27-11	4315-4316	3	_
27-12	4317-4321	NASZ	http://maven.renci.org/NeuroBridge/neurobridge#PlasminAssay
27-13	4322-4334	participants	_
27-14	4335-4339	were	_
27-15	4340-4351	outpatients	_
27-16	4352-4353	.	_

28-1	4354-4357	The	_
28-2	4358-4366	patients	_
28-3	4367-4371	were	_
28-4	4372-4380	assessed	_
28-5	4381-4386	using	_
28-6	4387-4390	the	_
28-7	4391-4399	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
28-8	4400-4403	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
28-9	4404-4412	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
28-10	4413-4421	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
28-11	4422-4427	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
28-12	4428-4429	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
28-13	4430-4435	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
28-14	4436-4437	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
28-15	4438-4441	and	_
28-16	4442-4445	the	_
28-17	4446-4451	Brief	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
28-18	4452-4463	Psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
28-19	4464-4470	Rating	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
28-20	4471-4476	Scale	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
28-21	4477-4478	(	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
28-22	4479-4483	BPRS	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
28-23	4484-4485	)	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
28-24	4486-4487	.	_

29-1	4488-4495	Stimuli	_
29-2	4496-4499	and	http://maven.renci.org/NeuroBridge/neurobridge#PhysicalMeasurement
29-3	4500-4509	Procedure	_
29-4	4510-4519	Following	_
29-5	4520-4521	a	_
29-6	4522-4529	hearing	_
29-7	4530-4534	test	_
29-8	4535-4536	,	_
29-9	4537-4549	participants	_
29-10	4550-4554	were	_
29-11	4555-4560	asked	_
29-12	4561-4563	to	_
29-13	4564-4567	lay	_
29-14	4568-4574	supine	_
29-15	4575-4581	inside	_
29-16	4582-4584	an	_
29-17	4585-4588	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
29-18	4589-4596	scanner	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
29-19	4597-4602	while	_
29-20	4603-4610	wearing	_
29-21	4611-4622	head-phones	_
29-22	4623-4624	.	_

30-1	4625-4628	The	_
30-2	4629-4633	head	_
30-3	4634-4636	of	_
30-4	4637-4641	each	_
30-5	4642-4653	participant	_
30-6	4654-4657	was	_
30-7	4658-4668	restrained	_
30-8	4669-4672	via	_
30-9	4673-4680	padding	_
30-10	4681-4687	behind	_
30-11	4688-4691	the	_
30-12	4692-4696	neck	_
30-13	4697-4700	and	_
30-14	4701-4708	between	_
30-15	4709-4712	the	_
30-16	4713-4717	head	_
30-17	4718-4721	and	_
30-18	4722-4725	the	_
30-19	4726-4730	coil	_
30-20	4731-4732	.	_

31-1	4733-4745	Participants	_
31-2	4746-4750	were	_
31-3	4751-4756	asked	_
31-4	4757-4759	to	_
31-5	4760-4764	keep	_
31-6	4765-4770	their	_
31-7	4771-4775	head	_
31-8	4776-4781	still	_
31-9	4782-4788	inside	_
31-10	4789-4792	the	_
31-11	4793-4800	scanner	_
31-12	4801-4804	and	_
31-13	4805-4807	to	_
31-14	4808-4813	focus	_
31-15	4814-4816	on	_
31-16	4817-4818	a	_
31-17	4819-4827	fixation	_
31-18	4828-4833	cross	_
31-19	4834-4843	presented	_
31-20	4844-4846	on	_
31-21	4847-4848	a	_
31-22	4849-4855	screen	_
31-23	4856-4857	.	_

32-1	4858-4861	All	_
32-2	4862-4870	auditory	_
32-3	4871-4878	stimuli	_
32-4	4879-4883	were	_
32-5	4884-4893	delivered	_
32-6	4894-4904	binaurally	_
32-7	4905-4912	through	_
32-8	4913-4916	the	_
32-9	4917-4928	head-phones	_
32-10	4929-4930	.	_

33-1	4931-4933	We	_
33-2	4934-4943	presented	_
33-3	4944-4952	auditory	_
33-4	4953-4964	stimulation	_
33-5	4965-4970	using	_
33-6	4971-4972	a	_
33-7	4973-4991	4-min-block-design	_
33-8	4992-5000	paradigm	_
33-9	5001-5005	with	_
33-10	5006-5007	8	_
33-11	5008-5014	blocks	_
33-12	5015-5017	of	_
33-13	5018-5020	15	_
33-14	5021-5022	s	_
33-15	5023-5025	of	_
33-16	5026-5030	rest	_
33-17	5031-5032	(	_
33-18	5033-5044	stimulation	_
33-19	5045-5048	OFF	_
33-20	5049-5050	)	_
33-21	5051-5054	and	_
33-22	5055-5057	15	_
33-23	5058-5059	s	_
33-24	5060-5062	of	_
33-25	5063-5074	stimulation	_
33-26	5075-5084	including	_
33-27	5085-5087	15	_
33-28	5088-5093	click	_
33-29	5094-5100	trains	_
33-30	5101-5102	(	_
33-31	5103-5114	stimulation	_
33-32	5115-5117	ON	_
33-33	5118-5119	)	_
33-34	5120-5121	.	_

34-1	5122-5124	In	_
34-2	5125-5130	total	_
34-3	5131-5132	,	_
34-4	5133-5135	we	_
34-5	5136-5145	presented	_
34-6	5146-5149	120	_
34-7	5150-5155	click	_
34-8	5156-5162	trains	_
34-9	5163-5166	for	_
34-10	5167-5171	each	_
34-11	5172-5176	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
34-12	5177-5184	session	_
34-13	5185-5186	.	_

35-1	5187-5189	We	_
35-2	5190-5199	conducted	_
35-3	5200-5204	four	_
35-4	5205-5209	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
35-5	5210-5218	sessions	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
35-6	5219-5223	with	_
35-7	5224-5233	different	_
35-8	5234-5239	sound	_
35-9	5240-5247	stimuli	_
35-10	5248-5251	for	_
35-11	5252-5256	each	_
35-12	5257-5264	subject	_
35-13	5265-5266	.	_

36-1	5267-5270	The	_
36-2	5271-5278	stimuli	_
36-3	5279-5283	were	_
36-4	5284-5288	1-ms	_
36-5	5289-5295	clicks	_
36-6	5296-5297	,	_
36-7	5298-5307	presented	_
36-8	5308-5318	binaurally	_
36-9	5319-5321	as	_
36-10	5322-5328	trains	_
36-11	5329-5331	of	_
36-12	5332-5338	clicks	_
36-13	5339-5342	for	_
36-14	5343-5347	each	_
36-15	5348-5357	frequency	_
36-16	5358-5359	(	_
36-17	5360-5362	20	_
36-18	5363-5364	,	_
36-19	5365-5367	30	_
36-20	5368-5369	,	_
36-21	5370-5372	40	_
36-22	5373-5374	,	_
36-23	5375-5378	and	_
36-24	5379-5384	80-Hz	_
36-25	5385-5386	)	_
36-26	5387-5388	.	_

37-1	5389-5393	Both	_
37-2	5394-5397	the	_
37-3	5398-5406	duration	_
37-4	5407-5409	of	_
37-5	5410-5413	the	_
37-6	5414-5419	click	_
37-7	5420-5426	trains	_
37-8	5427-5430	and	_
37-9	5431-5434	the	_
37-10	5435-5446	inter-train	_
37-11	5447-5455	interval	_
37-12	5456-5460	were	_
37-13	5461-5464	500	_
37-14	5465-5467	ms	_
37-15	5468-5469	,	_
37-16	5470-5473	and	_
37-17	5474-5477	the	_
37-18	5478-5483	click	_
37-19	5484-5490	trains	_
37-20	5491-5495	were	_
37-21	5496-5505	presented	_
37-22	5506-5510	with	_
37-23	5511-5513	an	_
37-24	5514-5523	intensity	_
37-25	5524-5526	of	_
37-26	5527-5532	80-dB	_
37-27	5533-5538	sound	_
37-28	5539-5547	pressure	_
37-29	5548-5553	level	_
37-30	5554-5555	.	_

38-1	5556-5559	The	_
38-2	5560-5565	order	_
38-3	5566-5568	of	_
38-4	5569-5577	sessions	_
38-5	5578-5581	was	_
38-6	5582-5597	counterbalanced	_
38-7	5598-5604	across	_
38-8	5605-5613	subjects	_
38-9	5614-5615	.	_

39-1	5616-5620	Data	_
39-2	5621-5632	Acquisition	_
39-3	5633-5635	We	_
39-4	5636-5645	conducted	_
39-5	5646-5649	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
39-6	5650-5655	using	_
39-7	5656-5657	a	_
39-8	5658-5663	1.5-T	http://maven.renci.org/NeuroBridge/neurobridge#2Level
39-9	5664-5671	Philips	http://maven.renci.org/NeuroBridge/neurobridge#2Level
39-10	5672-5679	scanner	http://maven.renci.org/NeuroBridge/neurobridge#2Level
39-11	5680-5684	with	_
39-12	5685-5686	a	_
39-13	5687-5695	standard	_
39-14	5696-5700	head	_
39-15	5701-5705	coil	_
39-16	5706-5707	,	_
39-17	5708-5715	located	_
39-18	5716-5718	at	_
39-19	5719-5722	the	_
39-20	5723-5731	National	_
39-21	5732-5740	Hospital	_
39-22	5741-5753	Organization	_
39-23	5754-5759	Hizen	_
39-24	5760-5771	Psychiatric	_
39-25	5772-5778	Center	_
39-26	5779-5780	.	_

40-1	5781-5783	We	_
40-2	5784-5788	used	_
40-3	5789-5797	standard	_
40-4	5798-5806	sequence	_
40-5	5807-5817	parameters	_
40-6	5818-5820	to	_
40-7	5821-5827	obtain	_
40-8	5828-5838	functional	_
40-9	5839-5845	images	_
40-10	5846-5847	,	_
40-11	5848-5850	as	_
40-12	5851-5858	follows	_
40-13	5859-5860	:	_
40-14	5861-5874	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
40-15	5875-5886	echo-planar	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
40-16	5887-5894	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
40-17	5895-5896	(	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
40-18	5897-5900	EPI	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
40-19	5901-5902	)	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
40-20	5903-5904	;	_
40-21	5905-5915	repetition	_
40-22	5916-5920	time	_
40-23	5921-5922	(	_
40-24	5923-5925	TR	_
40-25	5926-5927	)	_
40-26	5928-5929	=	_
40-27	5930-5934	3000	_
40-28	5935-5937	ms	_
40-29	5938-5939	;	_
40-30	5940-5944	echo	_
40-31	5945-5949	time	_
40-32	5950-5951	(	_
40-33	5952-5954	TE	_
40-34	5955-5956	)	_
40-35	5957-5958	=	_
40-36	5959-5961	45	_
40-37	5962-5964	ms	_
40-38	5965-5966	;	_
40-39	5967-5971	flip	_
40-40	5972-5977	angle	_
40-41	5978-5979	=	_
40-42	5980-5983	90°	_
40-43	5984-5985	;	_
40-44	5986-5991	field	_
40-45	5992-5994	of	_
40-46	5995-5999	view	_
40-47	6000-6001	(	_
40-48	6002-6005	FOV	_
40-49	6006-6007	)	_
40-50	6008-6009	=	_
40-51	6010-6013	230	_
40-52	6014-6015	×	_
40-53	6016-6019	230	_
40-54	6020-6022	mm	_
40-55	6023-6024	;	_
40-56	6025-6031	matrix	_
40-57	6032-6033	=	_
40-58	6034-6036	64	_
40-59	6037-6038	×	_
40-60	6039-6041	64	_
40-61	6042-6043	;	_
40-62	6044-6046	60	_
40-63	6047-6052	axial	_
40-64	6053-6059	slices	_
40-65	6060-6064	with	_
40-66	6065-6066	a	_
40-67	6067-6072	slice	_
40-68	6073-6082	thickness	_
40-69	6083-6085	of	_
40-70	6086-6087	4	_
40-71	6088-6090	mm	_
40-72	6091-6095	with	_
40-73	6096-6098	no	_
40-74	6099-6104	slice	_
40-75	6105-6108	gap	_
40-76	6109-6110	.	_

41-1	6111-6113	We	_
41-2	6114-6122	acquired	_
41-3	6123-6124	a	_
41-4	6125-6140	high-resolution	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
41-5	6141-6152	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
41-6	6153-6155	3D	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
41-7	6156-6166	anatomical	_
41-8	6167-6172	image	_
41-9	6173-6176	for	_
41-10	6177-6181	each	_
41-11	6182-6193	participant	_
41-12	6194-6201	between	_
41-13	6202-6205	the	_
41-14	6206-6216	functional	_
41-15	6217-6221	data	_
41-16	6222-6228	trials	_
41-17	6229-6230	.	_

42-1	6231-6236	Image	_
42-2	6237-6247	Processing	_
42-3	6248-6251	Raw	_
42-4	6252-6257	image	_
42-5	6258-6263	DICOM	_
42-6	6264-6269	files	_
42-7	6270-6274	were	_
42-8	6275-6284	converted	_
42-9	6285-6287	to	_
42-10	6288-6291	the	_
42-11	6292-6297	NIFTI	_
42-12	6298-6304	format	_
42-13	6305-6310	using	_
42-14	6311-6321	MRIConvert	_
42-15	6322-6323	(	_
42-16	6324-6331	Version	_
42-17	6332-6335	2.0	_
42-18	6336-6337	,	_
42-19	6338-6343	Lewis	_
42-20	6344-6350	Center	_
42-21	6351-6354	for	_
42-22	6355-6367	Neuroimaging	_
42-23	6368-6369	,	_
42-24	6370-6376	Oregon	_
42-25	6377-6378	)	_
42-26	6379-6380	.	_

43-1	6381-6386	Image	_
43-2	6387-6397	processing	_
43-3	6398-6401	and	_
43-4	6402-6413	statistical	_
43-5	6414-6422	analyses	_
43-6	6423-6427	were	_
43-7	6428-6437	performed	_
43-8	6438-6443	using	_
43-9	6444-6447	the	_
43-10	6448-6459	statistical	_
43-11	6460-6470	parametric	_
43-12	6471-6478	mapping	_
43-13	6479-6487	software	_
43-14	6488-6492	SPM8	_
43-15	6493-6494	(	_
43-16	6495-6503	Wellcome	_
43-17	6504-6514	Department	_
43-18	6515-6517	of	_
43-19	6518-6527	Cognitive	_
43-20	6528-6537	Neurology	_
43-21	6538-6539	,	_
43-22	6540-6546	London	_
43-23	6547-6548	,	_
43-24	6549-6555	United	_
43-25	6556-6563	Kingdom	_
43-26	6564-6565	)	_
43-27	6566-6570	with	_
43-28	6571-6577	Matlab	_
43-29	6578-6584	R2014a	_
43-30	6585-6586	(	_
43-31	6587-6590	The	_
43-32	6591-6595	Math	_
43-33	6596-6601	Works	_
43-34	6602-6606	Inc.	_
43-35	6607-6608	,	_
43-36	6609-6615	Natick	_
43-37	6616-6617	,	_
43-38	6618-6620	MA	_
43-39	6621-6622	)	_
43-40	6623-6624	.	_

44-1	6625-6628	The	_
44-2	6629-6634	first	_
44-3	6635-6639	five	_
44-4	6640-6647	volumes	_
44-5	6648-6650	of	_
44-6	6651-6655	each	_
44-7	6656-6659	EPI	_
44-8	6660-6665	image	_
44-9	6666-6669	run	_
44-10	6670-6674	were	_
44-11	6675-6683	excluded	_
44-12	6684-6686	to	_
44-13	6687-6692	allow	_
44-14	6693-6696	the	_
44-15	6697-6699	MR	_
44-16	6700-6706	signal	_
44-17	6707-6709	to	_
44-18	6710-6715	reach	_
44-19	6716-6717	a	_
44-20	6718-6723	state	_
44-21	6724-6726	of	_
44-22	6727-6738	equilibrium	_
44-23	6739-6740	.	_

45-1	6741-6744	All	_
45-2	6745-6752	volumes	_
45-3	6753-6755	of	_
45-4	6756-6766	functional	_
45-5	6767-6770	EPI	_
45-6	6771-6777	images	_
45-7	6778-6782	were	_
45-8	6783-6792	realigned	_
45-9	6793-6795	to	_
45-10	6796-6799	the	_
45-11	6800-6805	first	_
45-12	6806-6812	volume	_
45-13	6813-6815	of	_
45-14	6816-6820	each	_
45-15	6821-6828	session	_
45-16	6829-6831	to	_
45-17	6832-6839	correct	_
45-18	6840-6843	for	_
45-19	6844-6851	subject	_
45-20	6852-6858	motion	_
45-21	6859-6860	,	_
45-22	6861-6864	and	_
45-23	6865-6868	the	_
45-24	6869-6873	mean	_
45-25	6874-6884	functional	_
45-26	6885-6888	EPI	_
45-27	6889-6894	image	_
45-28	6895-6898	was	_
45-29	6899-6903	then	_
45-30	6904-6913	spatially	_
45-31	6914-6927	co-registered	_
45-32	6928-6932	with	_
45-33	6933-6936	the	_
45-34	6937-6947	anatomical	_
45-35	6948-6950	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
45-36	6951-6957	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
45-37	6958-6959	.	_

46-1	6960-6964	Each	_
46-2	6965-6978	co-registered	_
46-3	6979-6990	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
46-4	6991-7001	anatomical	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
46-5	7002-7007	image	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
46-6	7008-7011	was	_
46-7	7012-7022	normalized	_
46-8	7023-7027	into	_
46-9	7028-7029	a	_
46-10	7030-7038	standard	_
46-11	7039-7041	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
46-12	7042-7050	template	_
46-13	7051-7056	image	_
46-14	7057-7058	(	_
46-15	7059-7063	ICBM	_
46-16	7064-7067	152	_
46-17	7068-7069	)	_
46-18	7070-7071	,	_
46-19	7072-7077	which	_
46-20	7078-7085	defined	_
46-21	7086-7089	the	_
46-22	7090-7098	Montreal	_
46-23	7099-7111	Neurological	_
46-24	7112-7121	Institute	_
46-25	7122-7123	(	_
46-26	7124-7127	MNI	_
46-27	7128-7129	)	_
46-28	7130-7135	space	_
46-29	7136-7137	.	_

47-1	7138-7141	The	_
47-2	7142-7152	parameters	_
47-3	7153-7157	from	_
47-4	7158-7162	this	_
47-5	7163-7176	normalization	_
47-6	7177-7184	process	_
47-7	7185-7189	were	_
47-8	7190-7194	then	_
47-9	7195-7202	applied	_
47-10	7203-7205	to	_
47-11	7206-7210	each	_
47-12	7211-7221	functional	_
47-13	7222-7227	image	_
47-14	7228-7229	.	_

48-1	7230-7233	The	_
48-2	7234-7244	normalized	_
48-3	7245-7255	functional	_
48-4	7256-7262	images	_
48-5	7263-7267	were	_
48-6	7268-7276	smoothed	_
48-7	7277-7281	with	_
48-8	7282-7283	a	_
48-9	7284-7286	3D	_
48-10	7287-7291	8-mm	_
48-11	7292-7302	full-width	_
48-12	7303-7315	half-maximum	_
48-13	7316-7317	(	_
48-14	7318-7322	FWHM	_
48-15	7323-7324	)	_
48-16	7325-7333	Gaussian	_
48-17	7334-7340	Kernel	_
48-18	7341-7342	.	_

49-1	7343-7347	Time	_
49-2	7348-7354	series	_
49-3	7355-7359	data	_
49-4	7360-7362	at	_
49-5	7363-7367	each	_
49-6	7368-7373	voxel	_
49-7	7374-7378	were	_
49-8	7379-7389	temporally	_
49-9	7390-7398	filtered	_
49-10	7399-7404	using	_
49-11	7405-7406	a	_
49-12	7407-7411	high	_
49-13	7412-7416	pass	_
49-14	7417-7423	filter	_
49-15	7424-7428	with	_
49-16	7429-7430	a	_
49-17	7431-7437	cutoff	_
49-18	7438-7440	of	_
49-19	7441-7444	128	_
49-20	7445-7447	s.	_
49-21	7448-7459	Statistical	_
49-22	7460-7468	Analysis	_
49-23	7469-7471	We	_
49-24	7472-7476	used	_
49-25	7477-7484	one-way	_
49-26	7485-7493	analyses	_
49-27	7494-7496	of	_
49-28	7497-7505	variance	_
49-29	7506-7507	(	_
49-30	7508-7513	ANOVA	_
49-31	7514-7515	)	_
49-32	7516-7517	,	_
49-33	7518-7529	chi-squared	_
49-34	7530-7535	tests	_
49-35	7536-7537	,	_
49-36	7538-7541	and	_
49-37	7542-7549	t-tests	_
49-38	7550-7552	to	_
49-39	7553-7559	assess	_
49-40	7560-7565	group	_
49-41	7566-7577	differences	_
49-42	7578-7580	in	_
49-43	7581-7584	the	_
49-44	7585-7596	demographic	_
49-45	7597-7606	variables	_
49-46	7607-7608	.	_

50-1	7609-7611	We	_
50-2	7612-7621	performed	_
50-3	7622-7626	fMRI	_
50-4	7627-7638	statistical	_
50-5	7639-7647	analysis	_
50-6	7648-7650	on	_
50-7	7651-7654	the	_
50-8	7655-7667	preprocessed	_
50-9	7668-7672	EPIs	_
50-10	7673-7677	with	_
50-11	7678-7681	the	_
50-12	7682-7689	general	_
50-13	7690-7696	linear	_
50-14	7697-7702	model	_
50-15	7703-7704	(	_
50-16	7705-7708	GLM	_
50-17	7709-7710	)	_
50-18	7711-7716	using	_
50-19	7717-7718	a	_
50-20	7719-7728	two-level	_
50-21	7729-7737	approach	_
50-22	7738-7739	.	_

51-1	7740-7743	The	_
51-2	7744-7749	model	_
51-3	7750-7759	consisted	_
51-4	7760-7762	of	_
51-5	7763-7769	boxcar	_
51-6	7770-7779	functions	_
51-7	7780-7789	convolved	_
51-8	7790-7794	with	_
51-9	7795-7798	the	_
51-10	7799-7808	canonical	_
51-11	7809-7820	hemodynamic	_
51-12	7821-7829	response	_
51-13	7830-7838	function	_
51-14	7839-7840	,	_
51-15	7841-7844	and	_
51-16	7845-7849	then	_
51-17	7850-7854	used	_
51-18	7855-7857	as	_
51-19	7858-7861	the	_
51-20	7862-7872	regressors	_
51-21	7873-7876	for	_
51-22	7877-7880	the	_
51-23	7881-7891	regression	_
51-24	7892-7900	analysis	_
51-25	7901-7902	.	_

52-1	7903-7906	The	_
52-2	7907-7910	six	_
52-3	7911-7915	head	_
52-4	7916-7922	motion	_
52-5	7923-7933	parameters	_
52-6	7934-7935	,	_
52-7	7936-7943	derived	_
52-8	7944-7948	from	_
52-9	7949-7952	the	_
52-10	7953-7964	realignment	_
52-11	7965-7975	processing	_
52-12	7976-7977	,	_
52-13	7978-7982	were	_
52-14	7983-7987	also	_
52-15	7988-7992	used	_
52-16	7993-7995	as	_
52-17	7996-8006	regressors	_
52-18	8007-8009	to	_
52-19	8010-8016	reduce	_
52-20	8017-8020	the	_
52-21	8021-8027	motion	_
52-22	8028-8035	related	_
52-23	8036-8045	artifacts	_
52-24	8046-8047	.	_

53-1	8048-8050	On	_
53-2	8051-8054	the	_
53-3	8055-8060	first	_
53-4	8061-8066	level	_
53-5	8067-8069	of	_
53-6	8070-8078	analysis	_
53-7	8079-8080	,	_
53-8	8081-8091	individual	_
53-9	8092-8100	contrast	_
53-10	8101-8107	images	_
53-11	8108-8111	for	_
53-12	8112-8116	each	_
53-13	8117-8125	stimulus	_
53-14	8126-8132	versus	_
53-15	8133-8137	rest	_
53-16	8138-8142	were	_
53-17	8143-8151	computed	_
53-18	8152-8155	and	_
53-19	8156-8161	taken	_
53-20	8162-8164	to	_
53-21	8165-8168	the	_
53-22	8169-8175	second	_
53-23	8176-8181	level	_
53-24	8182-8185	for	_
53-25	8186-8200	random-effects	_
53-26	8201-8210	inference	_
53-27	8211-8212	.	_

54-1	8213-8215	On	_
54-2	8216-8219	the	_
54-3	8220-8226	second	_
54-4	8227-8232	level	_
54-5	8233-8234	,	_
54-6	8235-8243	contrast	_
54-7	8244-8250	images	_
54-8	8251-8254	for	_
54-9	8255-8262	stimuli	_
54-10	8263-8265	as	_
54-11	8266-8269	the	_
54-12	8270-8284	within-subject	_
54-13	8285-8292	factors	_
54-14	8293-8297	were	_
54-15	8298-8307	submitted	_
54-16	8308-8310	to	_
54-17	8311-8316	three	_
54-18	8317-8323	groups	_
54-19	8324-8325	(	_
54-20	8326-8328	HC	_
54-21	8329-8330	,	_
54-22	8331-8335	NASZ	_
54-23	8336-8337	,	_
54-24	8338-8342	AESZ	_
54-25	8343-8344	)	_
54-26	8345-8347	as	_
54-27	8348-8351	the	_
54-28	8352-8367	between-subject	_
54-29	8368-8375	factors	_
54-30	8376-8390	full-factorial	_
54-31	8391-8396	ANOVA	_
54-32	8397-8398	.	_

55-1	8399-8402	All	_
55-2	8403-8407	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
55-3	8408-8415	results	_
55-4	8416-8419	are	_
55-5	8420-8428	reported	_
55-6	8429-8431	at	_
55-7	8432-8433	a	_
55-8	8434-8446	significance	_
55-9	8447-8452	level	_
55-10	8453-8455	of	_
55-11	8456-8457	p	_
55-12	8458-8459	<	_
55-13	8460-8464	0.05	_
55-14	8465-8466	,	_
55-15	8467-8478	family-wise	_
55-16	8479-8484	error	_
55-17	8485-8486	(	_
55-18	8487-8490	FWE	_
55-19	8491-8492	)	_
55-20	8493-8503	-corrected	_
55-21	8504-8505	(	_
55-22	8506-8517	voxel-level	_
55-23	8518-8527	corrected	_
55-24	8528-8529	)	_
55-25	8530-8531	,	_
55-26	8532-8534	or	_
55-27	8535-8536	p	_
55-28	8537-8538	<	_
55-29	8539-8543	0.05	_
55-30	8544-8545	,	_
55-31	8546-8549	FWE	_
55-32	8550-8567	cluster-corrected	_
55-33	8568-8574	across	_
55-34	8575-8578	the	_
55-35	8579-8584	whole	_
55-36	8585-8590	brain	_
55-37	8591-8595	with	_
55-38	8596-8599	the	_
55-39	8600-8607	initial	_
55-40	8608-8613	voxel	_
55-41	8614-8623	threshold	_
55-42	8624-8626	at	_
55-43	8627-8628	p	_
55-44	8629-8630	<	_
55-45	8631-8636	0.001	_
55-46	8637-8638	,	_
55-47	8639-8650	uncorrected	_
55-48	8651-8652	.	_

56-1	8653-8655	To	_
56-2	8656-8665	determine	_
56-3	8666-8669	the	_
56-4	8670-8679	direction	_
56-5	8680-8682	of	_
56-6	8683-8686	the	_
56-7	8687-8705	frequency-by-group	_
56-8	8706-8717	interaction	_
56-9	8718-8719	,	_
56-10	8720-8722	we	_
56-11	8723-8732	extracted	_
56-12	8733-8741	contrast	_
56-13	8742-8748	values	_
56-14	8749-8751	by	_
56-15	8752-8763	identifying	_
56-16	8764-8767	the	_
56-17	8768-8775	primary	_
56-18	8776-8784	auditory	_
56-19	8785-8791	cortex	_
56-20	8792-8795	and	_
56-21	8796-8804	Brodmann	_
56-22	8805-8810	areas	_
56-23	8811-8813	41	_
56-24	8814-8817	and	_
56-25	8818-8820	42	_
56-26	8821-8823	as	_
56-27	8824-8831	regions	_
56-28	8832-8834	of	_
56-29	8835-8843	interest	_
56-30	8844-8845	(	_
56-31	8846-8849	ROI	_
56-32	8850-8851	)	_
56-33	8852-8853	s	_
56-34	8854-8859	using	_
56-35	8860-8867	MarsBar	_
56-36	8868-8869	(	_
56-37	8870-8874	http	_
56-38	8875-8876	:	_
56-39	8877-8902	//marsbar.sourceforge.net	_
56-40	8903-8904	)	_
56-41	8905-8906	.	_

57-1	8907-8909	We	_
57-2	8910-8915	chose	_
57-3	8916-8921	these	_
57-4	8922-8927	areas	_
57-5	8928-8935	because	_
57-6	8936-8939	the	_
57-7	8940-8944	ASSR	_
57-8	8945-8947	is	_
57-9	8948-8958	reportedly	_
57-10	8959-8965	evoked	_
57-11	8966-8968	in	_
57-12	8969-8971	or	_
57-13	8972-8976	near	_
57-14	8977-8980	the	_
57-15	8981-8988	primary	_
57-16	8989-8997	auditory	_
57-17	8998-9004	cortex	_
57-18	9005-9006	.	_

58-1	9007-9010	The	_
58-2	9011-9020	resulting	_
58-3	9021-9029	contrast	_
58-4	9030-9036	values	_
58-5	9037-9041	were	_
58-6	9042-9051	subjected	_
58-7	9052-9054	to	_
58-8	9055-9060	ANOVA	_
58-9	9061-9063	in	_
58-10	9064-9068	SPSS	_
58-11	9069-9073	with	_
58-12	9074-9077	the	_
58-13	9078-9083	three	_
58-14	9084-9090	groups	_
58-15	9091-9092	(	_
58-16	9093-9095	HC	_
58-17	9096-9097	,	_
58-18	9098-9102	NASZ	_
58-19	9103-9104	,	_
58-20	9105-9109	AESZ	_
58-21	9110-9111	)	_
58-22	9112-9115	for	_
58-23	9116-9120	each	_
58-24	9121-9124	ROI	_
58-25	9125-9126	,	_
58-26	9127-9130	and	_
58-27	9131-9133	we	_
58-28	9134-9138	used	_
58-29	9139-9149	Bonferroni	_
58-30	9150-9158	post-hoc	_
58-31	9159-9164	tests	_
58-32	9165-9167	to	_
58-33	9168-9172	test	_
58-34	9173-9176	the	_
58-35	9177-9188	differences	_
58-36	9189-9196	between	_
58-37	9197-9200	the	_
58-38	9201-9207	groups	_
58-39	9208-9209	.	_

59-1	9210-9212	To	_
59-2	9213-9222	visualize	_
59-3	9223-9226	the	_
59-4	9227-9238	time-course	_
59-5	9239-9241	of	_
59-6	9242-9245	the	_
59-7	9246-9255	responses	_
59-8	9256-9258	in	_
59-9	9259-9263	each	_
59-10	9264-9267	ROI	_
59-11	9268-9269	,	_
59-12	9270-9272	we	_
59-13	9273-9279	fitted	_
59-14	9280-9281	a	_
59-15	9282-9288	finite	_
59-16	9289-9296	impulse	_
59-17	9297-9305	response	_
59-18	9306-9307	(	_
59-19	9308-9311	FIR	_
59-20	9312-9313	)	_
59-21	9314-9319	model	_
59-22	9320-9322	in	_
59-23	9323-9330	MarsBar	_
59-24	9331-9333	to	_
59-25	9334-9337	the	_
59-26	9338-9342	data	_
59-27	9343-9344	.	_

60-1	9345-9349	This	_
60-2	9350-9358	involved	_
60-3	9359-9364	using	_
60-4	9365-9366	a	_
60-5	9367-9373	linear	_
60-6	9374-9379	model	_
60-7	9380-9382	to	_
60-8	9383-9390	provide	_
60-9	9391-9399	unbiased	_
60-10	9400-9409	estimates	_
60-11	9410-9412	of	_
60-12	9413-9416	the	_
60-13	9417-9424	average	_
60-14	9425-9431	signal	_
60-15	9432-9441	intensity	_
60-16	9442-9444	at	_
60-17	9445-9449	each	_
60-18	9450-9454	time	_
60-19	9455-9460	point	_
60-20	9461-9468	without	_
60-21	9469-9475	making	_
60-22	9476-9477	a	_
60-23	9478-9484	priori	_
60-24	9485-9496	assumptions	_
60-25	9497-9502	about	_
60-26	9503-9506	the	_
60-27	9507-9512	shape	_
60-28	9513-9515	of	_
60-29	9516-9519	the	_
60-30	9520-9531	hemodynamic	_
60-31	9532-9540	response	_
60-32	9541-9542	(	_
60-33	9543-9546	HDR	_
60-34	9547-9548	)	_
60-35	9549-9550	.	_

61-1	9551-9553	We	_
61-2	9554-9561	modeled	_
61-3	9562-9567	seven	_
61-4	9568-9580	time-windows	_
61-5	9581-9583	of	_
61-6	9584-9589	every	_
61-7	9590-9591	3	_
61-8	9592-9593	s	_
61-9	9594-9595	(	_
61-10	9596-9609	corresponding	_
61-11	9610-9612	to	_
61-12	9613-9616	the	_
61-13	9617-9619	TR	_
61-14	9620-9621	)	_
61-15	9622-9623	,	_
61-16	9624-9635	time-locked	_
61-17	9636-9638	to	_
61-18	9639-9642	the	_
61-19	9643-9648	onset	_
61-20	9649-9651	of	_
61-21	9652-9655	the	_
61-22	9656-9661	first	_
61-23	9662-9670	auditory	_
61-24	9671-9682	stimulation	_
61-25	9683-9684	.	_

62-1	9685-9688	The	_
62-2	9689-9696	average	_
62-3	9697-9703	signal	_
62-4	9704-9708	used	_
62-5	9709-9711	in	_
62-6	9712-9716	this	_
62-7	9717-9728	calculation	_
62-8	9729-9731	is	_
62-9	9732-9737	based	_
62-10	9738-9740	on	_
62-11	9741-9750	frequency	_
62-12	9751-9754	and	_
62-13	9755-9757	is	_
62-14	9758-9768	identified	_
62-15	9769-9771	as	_
62-16	9772-9775	the	_
62-17	9776-9781	value	_
62-18	9782-9784	of	_
62-19	9785-9792	percent	_
62-20	9793-9799	signal	_
62-21	9800-9806	change	_
62-22	9807-9810	for	_
62-23	9811-9814	the	_
62-24	9815-9819	mean	_
62-25	9820-9826	column	_
62-26	9827-9829	of	_
62-27	9830-9833	the	_
62-28	9834-9837	SPM	_
62-29	9838-9848	regression	_
62-30	9849-9857	analysis	_
62-31	9858-9859	.	_

63-1	9860-9862	We	_
63-2	9863-9872	performed	_
63-3	9873-9874	a	_
63-4	9875-9892	repeated-measures	_
63-5	9893-9898	ANOVA	_
63-6	9899-9903	with	_
63-7	9904-9908	time	_
63-8	9909-9915	window	_
63-9	9916-9917	(	_
63-10	9918-9921	0–3	_
63-11	9922-9923	,	_
63-12	9924-9927	3–6	_
63-13	9928-9929	,	_
63-14	9930-9933	6–9	_
63-15	9934-9935	,	_
63-16	9936-9940	9–12	_
63-17	9941-9942	,	_
63-18	9943-9948	12–15	_
63-19	9949-9950	,	_
63-20	9951-9956	15–18	_
63-21	9957-9958	,	_
63-22	9959-9962	and	_
63-23	9963-9968	18–21	_
63-24	9969-9970	s	_
63-25	9971-9972	)	_
63-26	9973-9975	as	_
63-27	9976-9977	a	_
63-28	9978-9993	within-subjects	_
63-29	9994-10000	factor	_
63-30	10001-10004	and	_
63-31	10005-10010	group	_
63-32	10011-10012	(	_
63-33	10013-10015	HC	_
63-34	10016-10017	,	_
63-35	10018-10022	NASZ	_
63-36	10023-10024	,	_
63-37	10025-10029	AESZ	_
63-38	10030-10031	)	_
63-39	10032-10034	as	_
63-40	10035-10036	a	_
63-41	10037-10053	between-subjects	_
63-42	10054-10060	factor	_
63-43	10061-10062	.	_

64-1	10063-10066	The	_
64-2	10067-10076	resulting	_
64-3	10077-10084	percent	_
64-4	10085-10091	signal	_
64-5	10092-10098	change	_
64-6	10099-10105	values	_
64-7	10106-10110	were	_
64-8	10111-10120	subjected	_
64-9	10121-10123	to	_
64-10	10124-10125	a	_
64-11	10126-10131	three	_
64-12	10132-10137	group	_
64-13	10138-10139	(	_
64-14	10140-10142	HC	_
64-15	10143-10144	,	_
64-16	10145-10149	NASZ	_
64-17	10150-10151	,	_
64-18	10152-10156	AESZ	_
64-19	10157-10158	)	_
64-20	10159-10164	ANOVA	_
64-21	10165-10167	in	_
64-22	10168-10172	SPSS	_
64-23	10173-10174	,	_
64-24	10175-10178	and	_
64-25	10179-10181	we	_
64-26	10182-10186	used	_
64-27	10187-10197	Bonferroni	_
64-28	10198-10206	post-hoc	_
64-29	10207-10212	tests	_
64-30	10213-10215	to	_
64-31	10216-10222	assess	_
64-32	10223-10226	the	_
64-33	10227-10238	differences	_
64-34	10239-10246	between	_
64-35	10247-10253	groups	_
64-36	10254-10255	.	_

65-1	10256-10258	We	_
65-2	10259-10266	applied	_
65-3	10267-10270	the	_
65-4	10271-10289	Greenhouse–Geisser	_
65-5	10290-10300	correction	_
65-6	10301-10304	for	_
65-7	10305-10318	inhomogeneity	_
65-8	10319-10321	of	_
65-9	10322-10330	variance	_
65-10	10331-10334	for	_
65-11	10335-10342	factors	_
65-12	10343-10347	with	_
65-13	10348-10349	>	_
65-14	10350-10351	2	_
65-15	10352-10358	levels	_
65-16	10359-10360	,	_
65-17	10361-10363	as	_
65-18	10364-10373	reflected	_
65-19	10374-10376	in	_
65-20	10377-10380	the	_
65-21	10381-10389	reported	_
65-22	10390-10391	p	_
65-23	10392-10398	values	_
65-24	10399-10400	.	_

66-1	10401-10404	For	_
66-2	10405-10408	the	_
66-3	10409-10415	period	_
66-4	10416-10420	with	_
66-5	10421-10424	the	_
66-6	10425-10432	largest	_
66-7	10433-10437	main	_
66-8	10438-10444	effect	_
66-9	10445-10447	of	_
66-10	10448-10453	group	_
66-11	10454-10460	during	_
66-12	10461-10469	auditory	_
66-13	10470-10481	stimulation	_
66-14	10482-10483	,	_
66-15	10484-10486	we	_
66-16	10487-10496	performed	_
66-17	10497-10510	correlational	_
66-18	10511-10519	analyses	_
66-19	10520-10527	between	_
66-20	10528-10541	hallucination	_
66-21	10542-10548	scores	_
66-22	10549-10551	in	_
66-23	10552-10555	the	_
66-24	10556-10561	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
66-25	10562-10563	(	_
66-26	10564-10567	all	_
66-27	10568-10572	AESZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
66-28	10573-10581	patients	_
66-29	10582-10585	had	_
66-30	10586-10594	auditory	_
66-31	10595-10609	hallucinations	_
66-32	10610-10611	)	_
66-33	10612-10615	and	_
66-34	10616-10620	BOLD	_
66-35	10621-10628	percent	_
66-36	10629-10635	signal	_
66-37	10636-10643	changes	_
66-38	10644-10645	.	_

67-1	10646-10652	Effect	_
67-2	10653-10658	sizes	_
67-3	10659-10662	are	_
67-4	10663-10672	expressed	_
67-5	10673-10675	as	_
67-6	10676-10681	Cohen	_
67-7	10682-10684	's	_
67-8	10685-10687	d.	_
67-9	10688-10691	The	_
67-10	10692-10700	Spearman	_
67-11	10701-10703	's	_
67-12	10704-10707	rho	_
67-13	10708-10711	was	_
67-14	10712-10716	used	_
67-15	10717-10720	for	_
67-16	10721-10734	correlational	_
67-17	10735-10743	analysis	_
67-18	10744-10745	.	_

68-1	10746-10749	For	_
68-2	10750-10753	all	_
68-3	10754-10765	statistical	_
68-4	10766-10771	tests	_
68-5	10772-10773	,	_
68-6	10774-10775	α	_
68-7	10776-10779	was	_
68-8	10780-10784	0.05	_
68-9	10785-10786	.	_

